Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — FY2022 Earnings Presentation
27 slides from Hyphens Pharma International's earnings presentation, Mar 6, 2023
Slide 1: SGX General Announcement: Results Briefing FY2022
3/6/23, 12:17 PM General Announcement::RESULTS BRIEFING FY2022 GENERAL ANNOUNCEMENT::RESULTS BRIEFING FY2022 Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details Announcement Titl
Slide 2: Results Briefing FY2022
HYPHENS PHARMA INTERNATIONAL LIMITED Results Briefing FY2022 6 March 2023
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: How has the business changed over the past 5 years?
HOW HAS THE BUSINESS CHANGED OVER THE PAST 5 YEARS?
Slide 5: People – the bedrock of our success
PEOPLE – THE BEDROCK OF OUR SUCCESS 533 533 449 449 149 201 417 364 27.4 384 18.0 248 85 116 2018 2022 2018 2022 2018 2022 Direct Employees Indirect Employees Managerial Non-Managerial Payroll (S$'mil)
Slide 6: Products: specialty pharma products growth
PRODUCTS Growing the core; Nurturing the new, seeding the future How our specialty pharma products have grown (2018 – 2022) Revenue (S$'mil) 120 100 95.7 80 64.4 62.0 62.0 65.6 60 40 20 0 2018 2019 2020 2021 2022
Slide 7: Products: proprietary products growth
PRODUCTS Growing the core; Nurturing the new, seeding the future How our proprietary products have grown (2018 – 2022) Revenue (S$‘mil) 25 23.4 20 19.1 18.1 14.5 15 13.2 10 5 0 2018 2019 2020 2021 2022
Slide 8: Seeding our future
SEEDING OUR FUTURE • Nabota: Just approved in Singapore (Jan 2023) • Meradan: Launched in Indonesia (4Q2022) • Pipeline products: – Ustekinumab, Lederlon and Winlevi – Those that Novem has licensed • Numerous new products in the Ceradan® / Ocean Health® stable
Slide 9: How our marketing has evolved
HOW OUR MARKETING HAS EVOLVED #1: E-commerce and digital marketing #2: Consumer healthcare (“CHC”) trade marketing – Ocean Health® and Ceradan® updated look and feel – Expanded our CHC trade marketing to Malaysia and Indonesia (online and offline promotions – instore displays, collaborations with ph
Slide 10: CSR (2018 – 2022)
CSR (2018 — 2022) HOSPITASELAANG: $150,000 E COVID Support Fund | F “| 23 mel i si |: j ay ‘WE CARE!
Slide 11: Maintaining dividend policy
MAINTAINING DIVIDEND POLICY Five-Year Dividend Payout FY2022 S$’000 FY2018 FY2019 FY2020 FY2021 (Proposed) HPIL proposed / final dividends 1,650 3,004 1,863 2,069 3,427 Profit to shareholders 5,410 6,530 6,163 6,846 11,351 Dividend payout* 30.5% 46.0% 30.2% 30.2% 30.2% Number of issued shares at RD
Slide 12: FY2022 Highlights
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 13: Creating new value as healthcare digitalises
CREATING NEW VALUE AS HEALTHCARE DIGITALISES 3.0
Slide 14: In-licensing of Winlevi for ASEAN countries from Cosmo
SUCCESSFUL IN-LICENSING OF WINLEVI® FOR 10 ASEAN COUNTRIES FROM COSMO PHARMACEUTICALS • New type of acne prescription medication approved by the U.S. FDA in nearly 40 years • Only topical cream that treats hormonal acne directly in the skin • Access to all future product extension of Winlevi ® for a
Slide 15: Financial Results
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 16: 1.1 Financial Performance
1.1 FINANCIAL PERFORMANCE Revenue (S$'mil) Profit After Tax (S$'mil) 11.4 162.3 121.0 125.9 115.9 116.3 6.5 6.8 6.2 5.4 2018 2019 2020 2021 2022 2018* 2019 2020** 2021** 2022 #Restated for FY2018-FY2020 to be consistent with FY2021 and FY2022 *Incl IPO exp S$0.9 million; **Incl JSS & Covid-related s
Slide 17: 1.1 Financial Performance (Cont'd)
1.1 FINANCIAL PERFORMANCE (CONT’D) Recurring EBITDA (S$'mil) 17.3 10.8 9.9 10.1 8.6 2018* 2019 2020** 2021# 2022 *excl IPO exp (S$0.9m) **excl JSS & COVID-related stock prov (S$0.7m net gain) #excl JSS & Novem acquisition exp (S$0.3m net exp)
Slide 18: 1.2 Income Statement
1.2 INCOME STATEMENT • Notes Revenue increased across all business segments and most geographical locations S$’000 FY2022 FY2021 YoY • Novem contributed S$17m in revenue Revenue 162,316 125,883 28.9% • Decline in other income due to absence of FX Gross Profit 62,809 48,083 30.6% gain, offset by writ
Slide 19: 1.3 Revenue by Business Segments
1.3 REVENUE BY BUSINESS SEGMENTS 160.0 140.0 120.0 59% Revenue S$'mil 100.0 51% 52% 80.0 56% 53% 60.0 15% 14% 12% 15% 40.0 11% 20.0 33% 34% 34% 33% 27% - FY2018 FY2019 FY2020 FY2021 FY2022 Specialty 64.4 62.0 62.0 65.6 95.7 Proprietary 13.2 14.5 18.1 19.1 23.4 Hypermart 38.4 39.8 40.9 41.2 43.2
Slide 20: 1.4 Revenue by Geographical Segments
1.4 REVENUE BY GEOGRAPHICAL SEGMENTS 160.0 140.0 120.0 52% Revenue S$'mil 100.0 50% 51% 46% 49% 80.0 60.0 34% 40.0 41% 37% 36% 33% 20.0 7% 7% 8% 9% 7% - 6% 6% 7% 8% 5% FY2018 FY2019 FY2020 FY2021 FY2022 Singapore 53.9 57.5 60.8 64.1 84.5 Vietnam 47.7 43.6 43.9 41.6 54.6 Malaysia 7.7 8.0 7.9 10.6 15.
Slide 21: 2 Financial Position
2 FINANCIAL POSITION S$’000 31 Dec 2022 31 Dec 2021* Total assets 114,469 99,191 Inventories 21,260 25,290 Trade & other receivables 31,106 28,722 Cash & cash equivalents 36,480 19,461 Total liabilities 44,197 44,455 Trade & other payables 35,077 33,563 Bank borrowings 4,479 6,075 Total equity 70,27
Slide 22: 3 Cashflow Statement
3 CASHFLOW STATEMENT S$’000 FY2022 FY2021 Cashflow from operating activities Profit before tax 14,291 8,256 Adjustments for non-cash items / non-op items 2,596 2,661 Changes in working capital 2,142 (3,464) Tax paid (2,152) (1,415) Cashflow from operating activities 16,877 6,038 Cashflow used in inv
Slide 23: 4 Proposed Dividend
4 PROPOSED DIVIDEND S$’000 Dividend Yield* Div / Net Profit FY2022 1.11 cents 3.1% 30.2% (subj to shareholders’ approval) FY2021 0.67 cent 1.9% 30.2% FY2020 0.62 cent 1.7% 30.2% FY2019 1 cent 2.8% 46.0% FY2018 0.55 cent 1.5% 30.5% *Yield is computed based on total dividends declared for the financia
Slide 24: Business Outlook
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 25: Our Growth Strategy
OUR GROWTH STRATEGY 1. Investment in proprietary brands 2. Internationalisation 3. Strengthen specialty pharma portfolio 4. Going Digital 5. Acquisitions 6. Embarked on flagship growth programme Scale-Up SG by Enterprise Singapore
Slide 26: Questions & Answers
Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 27: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — FY2022 Earnings Presentation on 6ix